BS_3F5PR9GS
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 109.62549277266754
- age_years
- 1.655
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.573
- G2M_CHECKPOINT+0.549
- MYC_TARGETS_V1+0.517
- MYC_TARGETS_V2+0.458
- MITOTIC_SPINDLE+0.295
- PANCREAS_BETA_CELLS+0.270
- SPERMATOGENESIS+0.240
- DNA_REPAIR+0.124
- HEDGEHOG_SIGNALING+0.000
- UNFOLDED_PROTEIN_RESPONSE-0.013
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.686
- INTERFERON_GAMMA_RESPONSE-0.615
- IL6_JAK_STAT3_SIGNALING-0.598
- TNFA_SIGNALING_VIA_NFKB-0.552
- INFLAMMATORY_RESPONSE-0.543
- ALLOGRAFT_REJECTION-0.486
- APOPTOSIS-0.472
- COMPLEMENT-0.459
- ANGIOGENESIS-0.457
- TGF_BETA_SIGNALING-0.448
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_7XQRH69M | medulloblastoma | — | 0.983 |
| 2 | BS_AM70R8RG | medulloblastoma | — | 0.981 |
| 3 | BS_YEB88D32 | medulloblastoma | — | 0.976 |
| 4 | BS_FCAKKZ20 | medulloblastoma | — | 0.972 |
| 5 | BS_TYAYZ9ZW | medulloblastoma | — | 0.970 |
| 6 | BS_09Z7TC35 | medulloblastoma | — | 0.970 |
| 7 | BS_W644VEVE | medulloblastoma | — | 0.968 |
| 8 | BS_5VQP0E6K | medulloblastoma | — | 0.968 |
| 9 | BS_NKRYMHEP | medulloblastoma | — | 0.967 |
| 10 | BS_45J79YTF | high-grade glioma | — | 0.967 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.573 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.549 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.517 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.458 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.295 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.124 | Idelalisib | — uncovered |